Cure of CLL
Derivatives of para-nitric oxide-donating acetylsalicylic acid provide novel compounds for the treatment of CLL.
Compound claims towards novel derivatives of para-NO-ASA: High selectivity, high activity, tested on different CLL cell populations, proven in a xenograft model of CLL
Development team comprising chemists and clinicians
Compounds may be suitable for the treatment of other neoplasias
effective and selective medicament for the treatment of neoplastic diseases or proliferative disorders
The present invention provides compounds acting as an effective and selective medicament for the treatment of neoplastic diseases or proliferative disorders, in particular compounds which induce selectively apoptosis of degenerated cells providing reduced side effects in living organisms
Licensing
24/09/2014 00:00:00
EP20140771921 20140924
- international:
A61K31/621; A61K31/695; A61P35/00; A61P35/02; C07C203/04; C07C247/10; C07C309/76; C07C69/76; C07F7/08
- cooperative:
A61K31/215; A61K31/235; A61K31/24; A61K31/621; C07C203/04; C07C247/10; C07C309/76; C07C69/75; C07C69/76; C07C69/78; C07C69/86; C07F7/081; C07F7/1804; C07C2601/14
Patent application
4045
德國
